Insider Purchases: Inside the Buy
Tag: Short Squeeze
🧥 G-III Apparel (GIII): CEO Buys $1.12M at $27.94 as Marc Jacobs Becomes the $1B Bet 👗👜
G-III CEO Morris Goldfarb just invested $1.12 million in GIII at $27.94 as the apparel group trades below book value and transforms its brand portfolio around owned labels and Marc Jacobs. With expanding Q2 margins, roughly 21% short float and major execution risks, is Wall Street putting this fashion turnaround on the clearance rack too soon?
🤖 Upstart (UPST): $7.65M Founder Buying Meets a 30.6% Short-Squeeze Fuse 💳⚡
Upstart CEO Paul Gu and Executive Chairman Dave Girouard have bought roughly $7.65 million of UPST stock. Now revenue is growing 42%, GAAP profitability has returned—and 30.6% of the float is short. We dissect one of fintech’s most fascinating battleground stocks.
🩺 Alphatec (ATEC): CEO’s $1M Buy, Positive Free Cash Flow & an 11% Short-Squeeze Fuse 🦾🦴
Alphatec CEO Pat Miles just put $1.01 million of his own money into ATEC at $8.81. With positive free cash flow, improving EBITDA, Valence robotics and 11% short interest, is this battered spine-medtech stock finally reaching its turnaround moment?
🎮 GameStop (GME): Insider Stacking, $5.4B Cash Pile, $4.9B eBay Stake & the Collectibles Pivot 📦🕹️
GameStop isn't merely the meme stock it used to be. With Ryan Cohen and Lawrence Cheng buying shares, record Q2 operating income, collectibles sales up 57%, $5.4 billion in financial assets and a $4.9 billion eBay stake, GME is evolving into a fascinating—and extremely volatile—special situation.
🛒 Albertsons (ACI): Wall Street Gave Up. One Executive Just Invested $1.96 Million.
Albertsons has disappointed Wall Street—but one executive just invested nearly $2 million of his own money. We examine the insider buy, valuation, operating cash flow, ACI Edge restructuring, dividend sustainability and whether ACI could become one of the market's more interesting turnaround stories.
🏰 RH (NYSE: RH): Insider Buying, 34% Short Interest, and a Luxury Turnaround Worth Watching
RH isn't just selling luxury furniture anymore—it's trying to redefine luxury living. With a major insider purchase, elevated short interest, ambitious global expansion, and Wall Street split on the outlook, RH may be one of today's most intriguing turnaround stories.
🏝️ The 125% Float Monopoly: Inside Oxford Industries' High-Conviction Floor and the 8-Day Island Squeeze
With insiders buying, institutions owning more than the float itself, a 7.5% dividend yield and Tommy Bahama still thriving, Oxford Industries presents one of the more unusual setups in retail.
🧠 Cognizant (CTSH): The Impossible Float Monopoly, Project Leap, and a 9x Multiple GARP Arbitrage
Cognizant may be one of the market's most overlooked AI transformation stories. Strong bookings, aggressive buybacks, and a surprisingly cheap valuation suggest investors may be pricing the company too pessimistically.
🍩 Krispy Kreme (DNUT): The 3G Mastermind, 7-Day Squeeze Trap, and the Great Post-IPO Cash Flow Resuscitation
Krispy Kreme shares remain down more than 80% from their highs, but insiders—including former 3G Capital executive Bernardo Hees—are buying aggressively. With free cash flow finally turning positive and margins improving, the iconic doughnut maker may be entering a new chapter.
🫁 Summit Therapeutics (SMMT): The Keytruda Challenger, the Insider Buying Spree, and the November FDA Showdown
Summit Therapeutics may be one of biotech's most fascinating high-risk, high-reward stories. Ivonescimab is taking aim at Keytruda, insiders keep buying shares, short interest remains elevated, and a major FDA decision looms in November 2026.